Professional
Added to YB: 2024-04-16
Pitch date: 2024-04-10
CORT [bullish]
Corcept Therapeutics Incorporated
+266.47%
current return
Author Info
No bio for this author
Company Info
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Market Cap
$7.9B
Pitch Price
$24.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
106.86
P/E
86.48
EV/Sales
10.02
Sector
Pharmaceuticals
Category
growth
ClearBridge Small Cap Strategy New Portfolio Holding: Corcept Therapeutics Incorporated
CORT: Biotech focused on endocrine, oncology, metabolic & neuro disorders. Korlym, for Cushing's Syndrome, at $482M sales despite new generic threat. Upcoming next-gen drug Ph3 data soon: better safety, more indications = larger market. Rare disease + specialty distribution limit generic risk.
Read full article (1 min)